CSBio CSBio

X
[{"orgOrder":0,"company":"Ona Therapeutics","sponsor":"Fund+","pharmaFlowCategory":"D","amount":"$33.6 million","upfrontCash":"Undisclosed","newsHeadline":"Fund+ Announces Investment in Ona Therapeutics EUR30 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Ona Therapeutics"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncomatryx Announces a \u20ac15 Million Capital Increase to Conduct Clinical Trials Against the Tumor Micro-environment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Oncomatryx"},{"orgOrder":0,"company":"EntreChem","sponsor":"AI Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"EntreChem"},{"orgOrder":0,"company":"SunRock Biopharma","sponsor":"Ellipses Pharma Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ellipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:TRAIL Fusion Protein","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"SunRock Biopharma"},{"orgOrder":0,"company":"SunRock Biopharma","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"SunRock Biopharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, Debiopharm will boost its ADC oncology pipeline through SunRock’s antibody portfolio, including SRB21, an anti-HER3-HER2 bispecific, integrating Debiopharm’s Multilink™ & AbYlink™ technologies to create innovative antibody drug conjugates (ADCs).

            Lead Product(s): SRB21

            Therapeutic Area: Oncology Product Name: SRB21

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Debiopharm

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement September 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Ellipses has been granted global rights to develop and commercialise EP0017 and will assume the full cost and responsibility for the remaining pre-clinical and clinical development of the compound.

            Lead Product(s): SRB22

            Therapeutic Area: Oncology Product Name: EP0017

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ellipses Pharma Limited

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            EC-8042 (redesignated AIT-102), is a targeted cancer therapy that inhibits the activity of SWI/SNF in certain tumors where SWI/SNF is mutated (such as Rhabdoid tumors) and in other tumors where SWI/SNF associates with oncogenic transcription factors.

            Lead Product(s): AIT-102

            Therapeutic Area: Oncology Product Name: AIT-102

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: AI Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition April 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            These funds, together with Oncomatryx recurring revenues from its licensing agreements with international biopharmaceutical companies, will be used for the clinical development of additional ADCs of Oncomatryx tumour-microenvironment pipeline including OMTX705.

            Lead Product(s): OMTX705

            Therapeutic Area: Oncology Product Name: OMTX705

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $16.0 million Upfront Cash: Undisclosed

            Deal Type: Financing April 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will allow Ona Therapeutics to complete the pre-clinical development in a variety of tumor types and to move its lead candidate into first clinical studies in patients with metastatic cancer in 2023.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Fund+

            Deal Size: $33.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing June 16, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY